CBD Beneficial in Reducing Drop Seizures for Lennox-Gastaut Syndrome Drop Seizures

Cannabidiol has demonstrated, in studies, to have antiepileptic properties and has had widespread success as a treatment therapy for various types of seizure disorders.

Lennox-Gastaut Syndrome (LGS) is severe form of epilepsy which often begins in early childhood.  One type of seizure that is common with Lennox-Gastaut Syndrome is a drop seizure, where the patient temporarily loses all muscle function, loses consciousness and collapses.  It is not uncommon for those suffering from drop seizures to experience multiple episodes per week.  Cannabidiol, or CBD, has demonstrated, in studies, to have antiepileptic properties and has had widespread success as a treatment therapy for various types of seizure disorders.

In a collaborative study involving 30 clinics, 225 people with Lennox-Gastaut syndrome participated in a double-blind study to evaluate the safety and efficacy of adding cannabidiol to their current conventional antiepileptic medication.  Patients ranged in age from 2 to 55 years old and were experiencing two or more drop seizures per week. 76 patients received 20mg of CBD, 73 patients received 10mg CBD and the remaining 76 received an equal volume of a placebo substance, each daily, for 14 weeks.  The results showed a definite decrease in drop seizures for those patients receiving CBD: a 41.9% decrease for the group receiving 20mg cannabidiol per day and a 37.2% decrease for the group receiving 10mg cannabidiol per day.  Compared to the placebo group, whose reduction was 17.2%, the study demonstrated a significant reduction in the number of drop seizures for those receiving CBD, in addition to, their current antiepileptic medications.

We are excited to review ongoing research which demonstrates the positive effects of cannabidiol on varying disorders and medical conditions.  To read more about the study mentioned above, please see here.

In-Vitro Study Shows Anti-inflammatory Properties of CBD for Allergic Contact Dermatitis

CBD was shown to elevate levels of anandamide, resulting in anti-inflammatory and anti-allergenic properties.

Dermatitis is a common problem with a wide range of causes; it involves excessive pro-inflammatory compounds in the skin, often resulting in an itchy rash or red swollen skin. Allergic Contact Dermatitis (ACD) involves the immune system overreacting to certain substances, sometimes even in very small amounts, that normally shouldn’t cause a reaction. Some of the most common examples are:

  • Dander from dogs, cats and other animals
  • Plant oils and compounds such as poison ivy and latex
  • Certain metals such as nickel and gold, often found in jewelry
  • Fragrances found in body and home products such as perfumes, deodorants, shampoos and cleaning products
  • Topical antibiotics common in first aid creams and ointments
  • Preservatives such as Quaternium 15, frequently found in cosmetic and industrial products

In June of 2018, research scientists created an in-vitro (meaning it was performed outside of a living organism, such as in a test tube or culture dish) model of ACD and measured the release of pro-inflammatory compounds in the presence of CBD and other phytocannabinoids. Based on their findings, CBD was shown to elevate levels of anandamide, an endogenous cannabinoid that activates CB2 receptors (such as along immune cells in the blood), resulting in anti-inflammatory and anti-allergenic properties. It was also shown to have no cytotoxic effect.

This study is very promising and warrants deeper investigation of topical CBD on humans and animals for relieving the symptoms of ACD. You can learn more about the study, found in the Journal of Pharmacology and Experimental Therapeutics, at: http://jpet.aspetjournals.org/content/365/3/652.

Article by:

Tristan Summerfield, Nutritionist and Herbalist
Nectar CBD National Sales and Education
sales@coloradowholesalecompany.com
719.345.2500 x2

I have been a natural health educator since 2007 and my passion is helping people and the Planet to thrive using time-tested and scientifically verified foods, herbs, medicinal mushrooms, and sustainable lifestyle practices. If you have a US-based health business for humans or animals, please contact me and I can give you more details and samples of our 100% organic, full-spectrum, Colorado-grown, hemp-CBD products!

CBD Effective at Managing RBD Sleep Disorder in Parkinson’s Patients

The study confirmed that CBD was successfully able to control RBD symptoms in Parkinson’s patients and was published in the Journal of Clinical Pharmacy and Therapeutics.

One of the many symptoms of Parkinson’s Disease is rapid eye movement sleep behavior disorder or RBD.  RBD occurs during normal rapid eye movement (REM) sleep patterns, but prevents the patient from experiencing the usual muscle paralysis occurring during REM sleep.  Throughout REM sleep, people experience vivid dreams and the muscle paralysis serves to keep the person still and resting.  During RBD, patients can physically act out their dreams, to some extent, leading to possible injury to themselves and/or their partners.  Yelling, swearing, pushing, punching and kicking during sleep are all common behaviors for the RBD sleep disorder.  Cannabidiol (CBD) is one of the major components of the hemp plant; it has proven to have a diverse pharmacological profile, while absent of psychoactive effects, which has led to extensive research as a treatment therapy option for various diseases and disorders.

Researchers at the University of São Paulo in the Department of Neuroscience and Behavior, in Brazil, tested the effects of cannabidiol on Parkinson’s patients suffering from RBD sleep disorder.  Patients received either 75mg or 300mg of CBD per day for a 6-week period. During the case study, all patients showed a “prompt and substantial reduction in the frequency of RBD-related events without side effects.”  Their study confirmed that CBD was successfully able to control RBD symptoms in Parkinson’s patients and was published in the Journal of Clinical Pharmacy and Therapeutics.

As the research surrounding this remarkable compound continues to progress, we look forward to reviewing the research. To read the full text of the study cited in this article, please see here.

CBD May Stop the Spread of Ovarian Cancer

Sullivan University College of Pharmacy in Louisville, Kentucky, researched the effects of CBD therapy on ovarian cancer cells.

Ovarian cancer accounts for approximately 2% of all new cancer cases diagnosed each year.  When diagnosed early, before the onset of metastasis, which is the migration of cancer cells throughout the body, ovarian cancer is fairly treatable.  There is currently an urgent need, however, to find an effective ovarian cancer treatment to prevent metastasis.  Cannabidiol (CBD), one of the main components of hemp, has been proven to be an effective anti-cancer treatment against multiple types of cancers in various studies.

In 2017, Sullivan University College of Pharmacy in Louisville, Kentucky, researched the effects of CBD therapy on ovarian cancer cells.  When two types of cancer cell lines were treated with hemp extract containing CBD, cancer cell migration was reduced.  In one line, metastasis was significantly slowed across all CBD dosages tested.  The other line, when treated with 2.5-3.2 micrometers of CBD per cell, showed a decrease in cell migration similar to the chemotherapy drug Cisplatin. Based on their results, CBD showed definite anti-metastatic properties on ovarian cancer cells.

While more research is needed to ascertain the viability of using CBD for treating ovarian cancer, preliminary research shows there is definite reason for continued study.  We anticipate seeing more studies examining the effects of CBD on cancer cells.

To read more about the study from Sullivan University, click here.

CBD Could Help Treat Diabetic Retinopathy

In a study performed by the Department of Pharmacology and Toxicology at the Medical College of Georgia, researchers studied the protective effects of cannabidiol (CBD) on rats with diabetic retinopathy.

One of the many complications of diabetes can be diabetic retinopathy.  Caused by damage to the blood vessels in the retina of the eye, diabetic retinopathy impairs eyesight and can possibly lead to blindness. In a study performed by the Department of Pharmacology and Toxicology at the Medical College of Georgia, researchers studied the protective effects of cannabidiol (CBD) on rats with diabetic retinopathy.  CBD is one of the main components of hemp and has been shown to have a regulatory effect on the body’s endocannabinoid system, as well as, a diverse pharmacological profile.

During the conducted study, rats were induced with diabetes and treated with CBD after 1, 2 or 4 weeks. The diabetes caused significant rises in oxidative stress, retinal neuronal cell death and vascular permeability; following CBD treatment, these symptoms were reduced. The CBD administered also prevented retinal cell death and vascular hyperpermeability, which is excessive leaking of fluid and proteins from the blood vessels. The combined results demonstrated that CBD could reduce neurotoxicity, inflammation and blood-retinal barrier breakdown in diabetic animals.

We look forward to reviewing more medical studies regarding CBD therapy and diabetes.  To read the study from the Medical College of Georgia, referenced above, please see here.

CBD Therapy Helps Young Girl with PTSD

CBD treatment effectively decreased her anxiety and she showed steady improvement of both sleep duration and quality. 

Research has proven cannabidiol (CBD) to be an effective natural treatment option for many conditions including anxiety and post-traumatic stress disorder (PTSD) due to its ability to regulate the body’s endocannabinoid system.  Current pharmaceutical treatment options for anxiety and PSTD often come with known, severe side effects, leading individuals to consider CBD.

Doctors at the University of Colorado School of Medicine in Fort Collins, Colorado, prescribed CBD as an alternate therapy for a ten year old girl who had suffered from sexual abuse and, in turn, developed PTSD.  Pharmaceuticals were providing partial symptom relief but the effects weren’t long-lasting and she struggled with the side effects.  The CBD treatment effectively decreased her anxiety and she showed steady improvement of both sleep duration and quality.

To read the case report discussed above in its entirety, please see the link here.

Cannabidiol Reduces Breast Cancer Tumor Size and Metastases

Preliminary research has shown CBD to be an effective, targeted and non-toxic option that could regulate the metastatic properties of breast and other cancers.

In an effort find new treatment therapies for breast cancer, researchers have begun to study cannabidiol, or CBD. Cannabidiol is one of the major non-psychoactive components of the hemp plant. CBD has become increasingly popular to treat a wide variety of ailments do to its ability to regulate the body’s endocannabinoid system. Preliminary research has shown CBD to be an effective, targeted and non-toxic option that could regulate the metastatic properties of breast and other cancers.

At the California Pacific Medical Center in San Francisco, California, researchers had previously reported that cannabidiol exhibits a very low toxicity profile and effectively down-regulates the Id-1 gene expression in breast cancer cells in cultures. Their continued research has shown that the down-regulation of Id-1 by CBD also inhibits the proliferative and invasive phenotype of breast cancer cells. Their studies have also shown that CBD therapy effectively reduces the primary tumor mass, as well as, the size and frequency of metastases in mice.

The important research being done at the California Pacific Medical Center further proves how significant CBD could be to the medical community. We eagerly await further studies demonstrating the effects cannabidiol has on cancer cells.

To read more about the study referenced above, please see here.

CBD Could be a New Treatment Therapy for MS, According to New Study

Neuroscientists conducted a study to examine the potential effects of cannabidiol on the PI3K/AKT/m/TOR pathway.

Multiple Sclerosis, or MS, is a chronic disease in which damage occurs to the sheaths of nerve cells in the brain and spinal cord. Often a progressive disease, symptoms can include pain, numbness, speech impairment and fatigue. Researchers have begun to study cannabidiol (CBD) as a possible treatment therapy, as CBD is one of the many compounds found in hemp and has a diverse pharmacological profile with little to no adverse side effects.

The PI3K/AKT/m/TOR pathway, an intracellular signaling pathway which regulates cell cycles, has become of interest to researchers studying MS, as it plays a major part in cellular quiescence, proliferation, cancer and longevity. Neuroscientists at the Contrada Casazza, in Italy, conducted a study in 2017 to examine the potential effects of cannabidiol on the PI3K/AKT/m/TOR pathway.

In their study, researchers induced mice with the most common model of MS.  After the disease symptoms began, the mice were treated with CBD at a rate of 10mg/kg of body weight daily and observed for clinical signs of MS.  After 28 days, the mice were euthanized and spinal tissues were sampled.  The results demonstrated a clear downregulation of the PI3K/AKT/m/TOR pathway and that CBD was effectively able to restore it.  Their data demonstrated the therapeutic efficacy of CBD, due to the reduction of pro-inflammatory cytokines and the promotion of cell neuron survival.  They concluded their study by stating that the, “results provide an interesting discovery about the regulation of the PI3K/AKT/m/TOR pathway by cannabidiol administration, that could be a new potential therapeutic target for MS management.”

This is exciting news for Multiple Sclerosis patients. We hope research will continue to investigate how CBD can regulate the PI3K/AKT/m/TOR pathway and how it could benefit those suffering from MS. To learn more about the study referenced above, click here.

CBD Could Offer Neuroprotection for Newborn Infants

This study recognizes the important role of CBD in treating neonatal HI injuries, in addition to, protecting newborns from long-term brain damage.

When babies are born unable to breathe properly, they can develop hypoxia-ischemia (HI), a condition which occurs when the brain doesn’t receive enough oxygen.  HI may cause long-term side effects, including brain damage, of varying severity.  With limited treatment options available to premature newborn and babies, researchers have been searching for an effective method to protect delicate brain cells.  Cannabidiol (CBD), a non-psychoactive cannabinoid, or chemical component of the hemp plant, has previously demonstrated short-term neuroprotective properties on the brain, following a HI injury, during clinical studies.

As a follow-up to previous studies, researchers at the Foundation for Biomedical Research in Madrid, Spain, examined the neuroprotective effects of CBD and if those effects were sustainable long-term.  Newborn rats sustained a HI injury, with some receiving CBD treatment alongside non-treated rats.  After 30 days, the rats were subjected to magnetic resonance imaging, histological evaluation, magnetic resonance spectroscopy and Western blotting to evaluate whether the CBD treatments had any lasting effects on the brain tissue. Their results showed that CBD effectively modulated brain excitotoxicity, oxidative stress and inflammation.  This study recognizes the important role of CBD in treating neonatal HI injuries, in addition to, protecting newborns from long-term brain damage.

To read more about the aforementioned study, please click here.

CBD May Improve Quality of Life for Parkinson’s Patients

Parkinson’s patients who received 300mg of CBD per day felt their quality of life was markedly improved.

Parkinson’s is a progressive disease of the central nervous system that effects movement, often causing tremors and difficulty speaking. Symptoms are caused by nerve cell damage in the brain which causes dopamine levels to drop.  There is currently no cure for Parkinson’s. There has, however, been a significant increase in both awareness and research since actor Michael J. Fox was diagnosed and founded the Foundation for Parkinson’s Research in 2000.

While there is currently no known cure for Parkinson’s, researchers have been attempting to find effective treatments to improve the quality of life of patients.  The endocannabinoid system, which regulates many of the body’s vital functions, is now being studied as a management tool for Parkinson’s symptoms.  Cannabidiol, or CBD, one of the major non-psychoactive components of the hemp plant, has been shown to help regulate the endocannabinoid system. Researchers at the University of São Paulo, in Brazil, conducted a study to better understand if CBD could improve the quality of life of those suffering from Parkinson’s.

Brazilian researchers created 3 groups of Parkinson’s patients of 7 people each.  The trial subjects had no other psychiatric conditions.  One week before treatments began, all patients were given the same tests measuring motor skills, symptom severity and quality of life. Of the 3 groups, one was used a control, receiving a daily placebo treatment, one was administered 75mg of CBD daily and the last group was administered 300mg CBD daily.  After treatment, the patients were given the same series of tests. While there were no significant changes in motor skills or symptoms, there was a drastic change in the test scores measuring quality of life.  Patients who received 300mg of CBD per day felt their quality of life was markedly improved.

While this study was conducted on a limited patient pool, researchers were confident in the results and expressed the need for further research, with larger trials, to continue studying the effects of CBD on Parkinson’s patients.  In the case of a progressive disease, with no known cure, quality of life is crucial to maintain.

To read more about the study from the University of São Paulo, please click here.